Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(hydroxymethyl)acylfulvene
2. 6-hydroxymethylacylfulvene
3. Hmaf Cpd
4. Mgi 114
5. Mgi-114
6. Mgi.114
1. Hmaf
2. Mgi 114
3. 158440-71-2
4. 6-hydroxymethylacylfulvene
5. (-)-irofulven
6. Mgi-114
7. Nsc 683863
8. (hydroxymethyl)acylfulvene
9. Nsc-683863
10. (5'r)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
11. 6b799ih05a
12. Lp-100
13. (r)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5h)inden)-7'(6'h)-one
14. 6-(hydroxymethyl)acylfulvene
15. Acylfulvene, 6-(hydroxymethyl)-
16. Irofulven [usan:inn]
17. Unii-6b799ih05a
18. Mgi.114
19. Irofulven [inn]
20. Irofulven [mi]
21. Irofulven (usan/inn)
22. Irofulven [usan]
23. Irofulven [who-dd]
24. Schembl8800
25. Chembl118218
26. Dtxsid50166423
27. Chebi:135002
28. Zinc3916310
29. Bdbm50410835
30. Nsc683863
31. Akos027256650
32. Db05786
33. (r)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-inden]-7'(6'h)-one
34. Hy-14429
35. Nci60_030149
36. Spiro(cyclopropane-1,5'(5h)-inden)-7'(6'h)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (r)-
37. Cs-0003353
38. D04614
39. Q6072197
| Molecular Weight | 246.30 g/mol |
|---|---|
| Molecular Formula | C15H18O3 |
| XLogP3 | -0.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 246.125594432 g/mol |
| Monoisotopic Mass | 246.125594432 g/mol |
| Topological Polar Surface Area | 57.5 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 558 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)
Radiation-Sensitizing Agents
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)
MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells. Once inside the cells, the compound binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or cell suicide. During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised.
ABOUT THIS PAGE
A Irofulven manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Irofulven, including repackagers and relabelers. The FDA regulates Irofulven manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Irofulven API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Irofulven manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Irofulven supplier is an individual or a company that provides Irofulven active pharmaceutical ingredient (API) or Irofulven finished formulations upon request. The Irofulven suppliers may include Irofulven API manufacturers, exporters, distributors and traders.
click here to find a list of Irofulven suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Irofulven DMF (Drug Master File) is a document detailing the whole manufacturing process of Irofulven active pharmaceutical ingredient (API) in detail. Different forms of Irofulven DMFs exist exist since differing nations have different regulations, such as Irofulven USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Irofulven DMF submitted to regulatory agencies in the US is known as a USDMF. Irofulven USDMF includes data on Irofulven's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Irofulven USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Irofulven suppliers with USDMF on PharmaCompass.
Irofulven Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Irofulven GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Irofulven GMP manufacturer or Irofulven GMP API supplier for your needs.
A Irofulven CoA (Certificate of Analysis) is a formal document that attests to Irofulven's compliance with Irofulven specifications and serves as a tool for batch-level quality control.
Irofulven CoA mostly includes findings from lab analyses of a specific batch. For each Irofulven CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Irofulven may be tested according to a variety of international standards, such as European Pharmacopoeia (Irofulven EP), Irofulven JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Irofulven USP).
LOOKING FOR A SUPPLIER?
